SecBot SecBot

XNCR drug pipeline

Xencor Inc · 2 rated drugs
$35.40
−4.6% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
35
IV 102% · HV 77%
Rated drugs
2
2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketUnknown — pivotal study start is planned for 2027, meaning FDA approval would likely be several years away if Phase 2/3 data are positive.

XmAb819 Updated Aug 31

What to watch

Watch the ESMO 2026 oral presentation (likely October 2026) for updated Phase 1 dose-expansion data, specifically whether the 25% ORR holds or improves in a larger cohort and whether the safety profile (primarily Grade 1-2 CRS, rash, GI events) remains manageable. The pivotal study start in 2027 is the next major milestone after that. XNCR's ~$26 stock price already reflects a mean analyst target of $29, limiting near-term upside absent a clear data beat.

Bull case
  • First-in-class mechanism: XmAb819 is the only ENPP3 x CD3 bispecific in clinical development, targeting an antigen highly expressed on ccRCC cells with a differentiated 2+1 format for tumor selectivity.
  • Encouraging early efficacy: 25% ORR in heavily pretreated, unselected ccRCC patients at the initial dose-escalation data cut is competitive for this refractory population and met internal criteria to advance to dose expansion.
  • Strong institutional support: BlackRock ($220M), PRIMECAP ($164M), RTW Investments ($109M), and RA Capital ($85M) are top holders as of Q2 2026, and multiple funds added or doubled positions in the quarter.
Bear case
  • Early-stage risk: XmAb819 is still in Phase 1 dose expansion, the pivotal study hasn't started yet (planned for 2027). Approval is years away and attrition risk for Phase 1 oncology assets is high.
  • Safety concerns: Cytokine release syndrome (CRS), rash, and GI toxicities were the most common adverse events. While primarily Grade 1-2, CRS is a known risk for T-cell engagers and could limit dosing or require mitigation strategies.
  • Competitive ccRCC landscape: Multiple approved therapies exist (TKIs, checkpoint inhibitors, HIF-2α inhibitors) and other bispecifics/T-cell engagers are in development for RCC, creating a crowded target.
● neutral
Impact
PhaseEarly-stage (Phase 1/2, likely)
Time to marketUnknown — early-stage asset; likely several years from potential approval if clinical trials succeed

XmAb541 Updated Aug 31

What to watch

XmAb541 is an early-stage, non-binary asset for Xencor. Watch for any initial clinical data readout (expected sometime in 2026 per company guidance) and whether the hearing toxicity signal materializes. The bigger near-term catalysts for XNCR are XmAb819 at ESMO (Oct 2026) and XmAb942 XENITH-UC interim analysis (year-end 2026).

Bull case
  • Received FDA Fast Track designation for germ cell tumors, which can accelerate development and review timelines (source: Xencor Q2 2026 8-K filing analysis).
  • Germ cell tumors are a niche oncology indication with high unmet need in relapsed/refractory settings, potentially offering a clear regulatory pathway.
  • Built on Xencor's validated XmAb bispecific antibody platform, which has produced multiple clinical-stage candidates.
Bear case
  • Hearing impairment toxicity is a noted risk that could limit commercial potential even if efficacy is established (source: Xencor Q2 2026 8-K filing analysis risks section).
  • Very limited public data available, no clinical trial results have been disclosed, making it difficult to assess probability of success.
  • Germ cell tumors are a small market, limiting peak revenue potential even in a best-case approval scenario.

Other drugs in filings and trials

no drug report yet

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
XmAb20717XmAb20717 in Advanced Biliary Tract CancersPhase 2Completed27Jul 13, 2026